When to Start Hydroxyurea for Cytoreduction Based on WBC Count
Start hydroxyurea for cytoreduction when the WBC count exceeds 10 × 10⁹/L in combination with platelet count >400 × 10⁹/L in polycythemia vera, or when the leukocyte count is higher than 15 × 10⁹/L in myeloproliferative neoplasms requiring cytoreductive therapy. 1
Disease-Specific WBC Thresholds
Polycythemia Vera (PV)
The European LeukemiaNet guidelines establish that leukocyte counts higher than 15 × 10⁹/L are indications to start cytoreductive therapy 1. More specifically, the NCCN defines uncontrolled myeloproliferation requiring treatment as:
- WBC count >10 × 10⁹/L AND platelet count >400 × 10⁹/L after 3 months of at least 2 g/day of hydroxyurea (for resistance criteria) 2
For initial treatment decisions in high-risk PV patients, hydroxyurea or interferon-alpha is first-line cytoreductive therapy at any age, though caution is advised in younger patients due to long-term carcinogenic risk 1.
Essential Thrombocythemia (ET)
The WBC threshold is used differently here—hydroxyurea resistance/intolerance is defined as:
- Platelet count >600 × 10⁹/L AND WBC count <2.5 × 10⁹/L at any dose (indicating excessive myelosuppression) 2
Critical Context: Risk Stratification Matters
Do not start cytoreductive therapy based on WBC alone in low-risk patients. Treatment decisions must incorporate:
- Age ≥60 years or history of thrombosis = high-risk requiring cytoreduction 1
- Low-risk patients should receive only aspirin and phlebotomy (for PV), regardless of WBC count 2
Emergency Situations: Hyperleukocytosis
In acute leukemia with WBC >100 × 10⁹/L, hydroxyurea serves as emergency cytoreduction to prevent leukostasis syndrome:
- Dose: 50-100 mg/kg orally once daily until blast count <100 × 10⁹/L 3
- This reduces WBC by approximately 50% after one dose 3
- Pre-treatment with hydroxyurea in hyperleukocytic AML (WBC >50 × 10⁹/L) reduces early mortality compared to immediate chemotherapy 4
Important Caveats
Avoid routine hydroxyurea pre-treatment in chronic myeloid leukemia (CML). Despite historical practice, contemporary evidence shows no benefit from hydroxyurea cytoreduction before TKI initiation—it may actually delay definitive therapy and worsen outcomes 5, 6. Reserve hydroxyurea in CML only for symptomatic leukostasis or when TKI access is unavoidably delayed.
Monitor weekly complete blood counts once hydroxyurea is started, as myelosuppression is the primary dose-limiting toxicity 7. Leukopenia typically manifests first, followed by thrombocytopenia and anemia 7.
Dose adjustments: Reduce hydroxyurea dose by 50% if creatinine clearance <60 mL/min or in end-stage renal disease 7.
The WBC threshold of >10-15 × 10⁹/L serves as a trigger for cytoreduction only when combined with appropriate risk stratification and other disease features—it is not an absolute standalone criterion.